Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diclofenac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 8/20 | 1.00 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 1.00 |
| ▸ | CXCL8 | P10145 | 4/20 | 1.00 |
| ▸ | TTR | P02766 | 3/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 1/20 | 1.00 |
| ▸ | UGT1A9 | O60656 | 1/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | MT-CO2 | P00403 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | UGT1A6 | P19224 | 1/20 | 1.00 |
| ▸ | UGT1A1 | P22309 | 1/20 | 1.00 |
| ▸ | CXCR1 | P25024 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | AGTR2 | P50052 | 1/20 | 1.00 |
| ▸ | NR1I3 | Q14994 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 1.00 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 1.00 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diclofenac SCHEMBL2799 | 1.00 | PTGS2 (1.00) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL996716 | 1.00 | PTGS2 (1.00) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL2216520 | 0.98 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL418230 | 0.98 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL4614418 | 0.98 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL1178502 | 0.98 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL1231246 | 0.98 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL22370200 | 0.98 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL22129258 | 0.98 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 | |
| Diclofenac SCHEMBL40785 | 0.98 | PTGS2 (0.97) | PTGS2CXCL8TTRPTGS1AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20260041660-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | CHANG RICHARD L (US) | 2026-02-12 | — | — | US | claimed |
| US-20250262178-A1 | NANOEMULSION COMPRISING DICLOFENAC | HALEON CH SARL (CH) | 2025-08-21 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| WO-2025050106-A1 | SUSTAINED RELEASE OCULAR IMPLANTS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-03-06 | — | — | WO | claimed |
| EP-4512783-A2 | METHOD FOR TREATING WASTE WATER AND WASTE WATER TREATMENT PLANT | Städt. Werke AG (DE) | 2025-02-26 | — | — | EP | claimed |
| US-20240382597-A1 | FORMULATIONS OF ANTI-INFLAMMATORY AGENTS COMPRISING MSM WITH ENHANCED SOLUBILITY IN WATER | LIVIONEX INC (US) | 2024-11-21 | — | — | US | claimed |
| US-20240342125-A1 | METHOD FOR INHIBITING GENERATION OF DICLOFENAC INDOLINONES | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2024-10-17 | — | — | US | claimed |
| EP-4429635-A1 | SELF-EMULSIFYING OIL-IN-WATER MICROEMULSION OR NANOEMULSION, AND EMULSIFYING COMPOSITION | URSAPHARM Arzneimittel GmbH (DE) | 2024-09-18 | — | — | EP | claimed |
| EP-4168068-A1 | ATOMIC LAYER DEPOSITION COATED PHARMACEUTICAL PACKAGING AND IMPROVED SYRINGES AND VIALS, E.G. FOR LYOPHILIZED/COLD-CHAIN DRUGS/VACCINES | SiO2 Medical Products, Inc. (US) | 2023-04-26 | — | — | EP | claimed |
| EP-3319637-B1 | USE OF POTASSIUM HYDROXIDE IN THE TREATMENT OF ACTINIC KERATOSIS | INFECTOPHARM ARZNEIMITTEL UND CONSILIUM GMBH (DE) | 2022-11-09 | — | — | EP | claimed |
| US-20220298033-A1 | Method and System for Treating Wastewater | KLEIN, HARALD (DE) | 2022-09-22 | — | — | US | claimed |
| US-20220244247-A1 | PECVD COATED PHARMACEUTICAL PACKAGING | OAKTREE FUND ADMINISTRATION, LLC | 2022-08-04 | — | — | US | claimed |
| EP-3274085-B1 | HYBRID SORBENT COMPOSITES COMPRISING MINERAL CLAY FOR REMOVAL OF ORGANIC-BASED MATERIALS | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2022-06-15 | — | — | EP | claimed |
| CN-111909221-B | Metal-organic framework material for visible light catalysis styrene bifunctional reaction, and preparation method and application thereof | 江苏师范大学 | 2022-06-03 | — | — | CN | claimed |
| WO-2022109619-A1 | POLYMER VIALS HAVING STANDARD EXTERNAL DIMENSIONS AND REDUCED INTERNAL VOLUME | SIO2 MEDICAL PRODUCTS, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| US-20220161969-A1 | PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS | OAKTREE FUND ADMINISTRATION, LLC | 2022-05-26 | — | — | US | claimed |
| US-11298293-B2 | PECVD coated pharmaceutical packaging | SIO2 MEDICAL PRODUCTS, INC. (US) | 2022-04-12 | — | — | US | claimed |
| CN-216074514-U | A making beating system for improving paper opacity | 东营华泰清河实业有限公司 | 2022-03-18 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382597-A1 | FORMULATIONS OF ANTI-INFLAMMATORY AGENTS COMPRISING MSM WITH ENHANCED SOLUBILITY IN WATER | TNF, CD14, CXCL8 | PTGS2 34/4885PTGS1 15/4885CXCL8 3/4885 |
| US-20260041660-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | TSLP, MAVS, PLAA | PTGS2 81/4885PTGS1 97/4885CXCL8 106/4885 |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | MEN1, MYO1G, IL2 | PTGS2 3239/4885PTGS1 2336/4885CXCL8 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.